Dinesh Shah

Percutaneous transluminal coronary angioplasty and stenting for cocaine-induced acute myocardial infarction: A case report and review

Cocaine‐induced myocardial infarction has been well reported. Likewise, there are numerous reports of patients with cocaine‐induced myocardial infarction being treated conservatively with nitroglycerin, verapamil, and thrombolytics. However, based on a Medline search from 1977 to 1998 (with the keywords cocaine and angioplasty), there have been no reports in English of cocaine‐induced myocardial infarction being treated with catheter‐based intervention. We report such a case, as well as review what is known about the pathophysiology of cocaine‐induced coronary arteriopathy and myocardial infarction. Cathet. Cardiovasc. Intervent. 49:447–451, 2000.

A novel nanocarrier sirolimus-coated balloon for coronary interventions: 12-Month data from the Nanoluté Registry

BACKGROUNDnThe aim of the Nanoluté registry was to observe the clinical performance of a novel sirolimus coated balloon (SCB) (Concept Medical Research Private Limited, India) for the treatment of coronary de-novo and restenotic lesions.nnnMETHODSnAll patients treated with SCB between July 2012 and September 2015 were enrolled at Indian centres and clinically followed for 1, 3, 6 and 12u202fmonths post-procedure. Primary endpoints were procedural success and device-oriented adverse cardiac events (DOCE) at 12u202fmonths. DOCE were defined as a composite of cardiac death, target lesion revascularization (TLR) and target vessel-myocardial infarction.nnnRESULTSnA total of 394 SCB were used in 332 patients to treat 356 lesions. In-stent restenosis and small coronary vessel disease occurred in 46% and 43% of the patients respectively. Mean balloon length and diameter (averageu202f±u202fSD) were 21.83u202f±u202f6.70u202fmm and 2.69u202f±u202f0.45u202fmm respectively. All patients with 1u202fyear follow-up were included. Overall DOCE rate was 4.2% (nu202f=u202f14) which included death 0.3% (nu202f=u202f1), TLR 3.6% (nu202f=u202f12) and myocardial infarction 0.3% (nu202f=u202f1).nnnCONCLUSIONnThe Nanoluté prospective registry, is the first clinical evidence of the safety and feasibility of this type of SCB, both in patients with in-stent restenosis or de novo lesions.